BioNTech SE (BNTX) Receives a Hold from Goldman Sachs

In a report released today, Chris Shibutani from Goldman Sachs maintained a Hold rating on BioNTech SE (BNTXResearch Report), with a price target of $299.00. The company’s shares closed last Wednesday at $217.69.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 23.7% and a 47.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Entrada Therapeutics Inc, Johnson & Johnson, and Merck & Company.

BioNTech SE has an analyst consensus of Moderate Buy, with a price target consensus of $295.09.

See Insiders’ Hot Stocks on TipRanks >>

Based on BioNTech SE’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $6.09 billion and net profit of $3.21 billion. In comparison, last year the company earned revenue of $67.5 million and had a GAAP net loss of $210 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed